News | News By Subject | News by Disease News By Date | Search News

Cirrhosis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Shire (SHPG) Terminates Milestone Payments to Former Lumena Shareholders After Liver Drug Fails     10/23/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Intercept Pharmaceuticals (ICPT) Reports Additional Positive Data From POISE Trial At EASL Late-Breaker Session     4/14/2014
Intercept Pharmaceuticals (ICPT) Drug Scores Pivotal Phase 3 Win Against Rare Liver Disease     3/18/2014
Ikaria Inc.'s LUCASSIN® Approved in Australia     4/24/2012
Protein Design Labs, Inc. (PDLI) And Orphan Therapeutics, LLC Report Fast Track Designation For Terlipressin In Type 1 Hepatorenal Syndrome     4/21/2005

News from Around the Web
Drinking Coffee May Reduce Liver Cirrhosis Risk, Study Published In Alimentary Pharmacology And Therapeutics Reveals     2/2/2016
New Genetic Link Found For Alcohol-Related Liver Cirrhosis, University of Cincinnati Study     3/31/2015
Drinking Coffee Reduces Mortality Risk From Liver Cirrhosis, National University of Singapore (NUS) Study     4/3/2014
Cholesterol Regulator Plays Key Role in Development of Liver Scarring, Cirrhosis, University of California, Los Angeles (UCLA) Study Finds     3/31/2011
Statins Linked to Better ICU Survival, Swedish Covenant Hospital Study     11/4/2010
Inflammation May Be Common Thread Behind Nervous And Heart Rhythm Problems In Cirrhosis, American Physiological Society Study     2/18/2009
Anti-fibrotic Mechanism Of A Chinese Medicinal Herb May Inspire Drug Development, Beijing Genomics Institute Study     5/2/2008
Man-Made Molecules Reverse Liver Cirrhosis In Rats     3/31/2008
Gene Variation May Elevate Risk of Liver Tumor in Patients with Cirrhosis     1/2/2008
Plasma Serotonin Levels can Correlate with Degree of Liver Insufficiency     11/5/2007
Liver Regeneration may be Simpler than Previously Thought     4/12/2007
Coffee May Reduce Risk Of Cirrhosis     6/13/2006
Nausea Drug Fails Against Cirrhosis-Linked Fatigue     6/13/2005
Stem Cells "To Treat Liver Harm"     12/16/2004
MMP-8 Gene Delivery Quells Cirrhosis In Rats     4/13/2004

Press Releases
Tobira Announces Publication Of Phase 1 Study Results Showing Cenicriviroc Safety In Cirrhotic Patients     5/13/2016
Bristol-Myers Squibb (BMY) Reports Fourth Quarter And Full Year 2015 Financial Results     1/28/2016
U.S. FDA Grants Priority Review To AbbVie (ABBV) For Supplemental New Drug Application For VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) Without Ribavirin In Genotype 1b Chronic Hepatitis C Virus Patients With Compensated Cirrhosis     1/7/2016
Merck & Co. (MRK) To Release Findings From Integrated Analysis Of Six Phase 2 And 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir In Patients With Chronic Hepatitis C Genotype 1, 4 Or 6 Infection And Compensated Cirrhosis At The Liver Meeting     11/16/2015
Tobira Therapeutics Inc. Reports Third Quarter 2015 Financial Results     11/11/2015
Exalenz Bioscience Announces Collaboration With Galectin Therapeutics To Use BreathID To Monitor Patients With Cirrhosis Associated With NASH     8/3/2015
AbbVie (ABBV) Presents New Data For Its Investigational Hepatitis C Treatment In Japanese Patients With And Without Cirrhosis     5/27/2015
Synageva BioPharma (GEVA) Starts Rolling Submission Of A Biologics License Application To The FDA For Sebelipase Alfa     10/22/2014
Intercept Pharmaceuticals (ICPT) Announces That FDA Grants Fast Track Designation To Obeticholic Acid For The Treatment Of Patients With Primary Biliary Cirrhosis     5/29/2014
Data From Intercept Pharmaceuticals (ICPT)'s Pivotal Phase 3 POISE Trial Of Its FXR Agonist Obeticholic Acid To Treat Primary Biliary Cirrhosis And Other Key Obeticholic Acid Data To Be Presented At EASL 2014     4/7/2014
Galectin Therapeutics Receives U.S. Patent for Second Drug Class to Treat Chronic Liver Disease With Fibrosis (Scarring) and Cirrhosis     11/26/2012
Celera Genomics Group-an Applera Corp. Business (CRA) Publishes Data Validating Cirrhosis Risk Score as a Predictor of Cirrhosis in Chronic Hepatitis C Patients     4/27/2007
Axcan Pharma (AXCA) Launches URSO Forte(TM) In The U.S.     11/2/2004
GlaxoSmithKline (GSK) Release: A Study Showing EPIVIR-HBV(R) (lamivudine) Significantly Delays Liver Complications From Chronic Hepatitis B Is Published By The New England Journal of Medicine     10/7/2004
Axcan Pharma (AXCA) Release: URSO 500 Mg Tablets Approved In The U.S. For The Treatment Of Primary Biliary Cirrhosis     7/26/2004

//-->